• Christina A Ortmann, David G Kent, Jyoti Nangalia, Yvonne Silber, David C Wedge, Jacob Grinfeld, E Joanna Baxter, Charles E Massie, Elli Papaemmanuil, Suraj Menon, Anna L Godfrey, Danai Dimitropoulou, Paola Guglielmelli, Beatriz Bellosillo, Carles Besses, Konstanze Döhner, Claire N Harrison, George S Vassiliou, Alessandro Vannucchi, Peter J Campbell, and Anthony R Green.
• Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Stem Cell Institute (C.A.O., D.G.K., J.N., Y.S., J.G., E.J.B., C.E.M., A.L.G., D.D., A.R.G.) and Department of Hematology (C.A.O., D.G.K., J.N., Y.S., J.G., E.J.B., C.E.M., A.L.G., D.D., G.S.V., P.J.C., A.R.G.), University of Cambridge, Department of Haematology, Addenbrooke's Hospital (C.A.O., J.N., J.G., E.J.B., A.L.G., G.S.V., P.J.C., A.R.G.), Wellcome Trust Sanger Institute (D.C.W., E.P., G.S.V., P.J.C.), and Cancer Research U.K. Cambridge Institute, Li Ka Shing Centre (S.M.), Cambridge, and Guy's and St. Thomas' National Health Service Foundation Trust, Guy's Hospital, London (C.N.H.) - all in the United Kingdom; Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Florence, Italy (P.G., A.V.); Departments of Pathology (B.B.) and Hematology (C.B.), Hospital del Mar, Barcelona; and the Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany (K.D.).
• N. Engl. J. Med. 2015 Feb 12; 372 (7): 601612601-612.

BackgroundCancers result from the accumulation of somatic mutations, and their properties are thought to reflect the sum of these mutations. However, little is known about the effect of the order in which mutations are acquired.MethodsWe determined mutation order in patients with myeloproliferative neoplasms by genotyping hematopoietic colonies or by means of next-generation sequencing. Stem cells and progenitor cells were isolated to study the effect of mutation order on mature and immature hematopoietic cells.ResultsThe age at which a patient presented with a myeloproliferative neoplasm, acquisition of JAK2 V617F homozygosity, and the balance of immature progenitors were all influenced by mutation order. As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2-first patients") had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro. Mutation order influenced the proliferative response to JAK2 V617F and the capacity of double-mutant hematopoietic cells and progenitor cells to generate colony-forming cells. Moreover, the hematopoietic stem-and-progenitor-cell compartment was dominated by TET2 single-mutant cells in TET2-first patients but by JAK2-TET2 double-mutant cells in JAK2-first patients. Prior mutation of TET2 altered the transcriptional consequences of JAK2 V617F in a cell-intrinsic manner and prevented JAK2 V617F from up-regulating genes associated with proliferation.ConclusionsThe order in which JAK2 and TET2 mutations were acquired influenced clinical features, the response to targeted therapy, the biology of stem and progenitor cells, and clonal evolution in patients with myeloproliferative neoplasms. (Funded by Leukemia and Lymphoma Research and others.).

29 keywords...

hide…